人工智能(AI)用于肺结节:AJR AI应用特别系列
本文综述了AI在肺结节影像评估中的应用,包括结节检测与表征、预后评估、图像后处理(如X线肋骨抑制、CT血管抑制)及非判读性报告与随访管理;指出尽管AI工具快速发展且部分获FDA批准,临床整合仍有限,面临泛化性、监管、实施技术和人类怀疑等挑战,尚需进一步验证及患者结局获益证据。
要点
- AI可用于肺结节检测、表征及预后评估,并辅助影像后处理与随访管理。
- AI工具获FDA批准但临床整合有限,障碍包括泛化性、监管、技术及人类怀疑。
- 尚需进一步验证AI临床效用及患者结局获益。
核心结论
- AI在肺结节影像评估中应用前景广泛,但临床实施仍面临泛化性、监管、技术及人类怀疑等挑战,需进一步验证及患者结局获益证据。
研究设计与样本
- 本文为AJR AI应用特别系列的综述,检索范围与纳入文献未在原文中报告。
局限性
- 原文指出AI工具临床采用面临泛化性、监管问题、实施技术障碍及人类怀疑等挑战。
- 原文指出尚需进一步验证AI工具临床使用及患者结局获益证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Interest in artificial intelligence (AI) applications for lung nodules continues to grow among radiologists, particularly with the expanding eligibility criteria and clinical utilization of lung cancer screening CT. AI has been heavily investigated for detecting and characterizing lung nodules and for guiding prognostic assessment. AI tools have also been used for image postprocessing (e.g., rib suppression on radiography or vessel suppression on CT) and for noninterpretive aspects of reporting and workflow, including management of nodule follow-up. Despite growing interest in and rapid development of AI tools and FDA approval of AI tools for pulmonary nodule evaluation, integration into clinical practice has been limited. Challenges to clinical adoption have included concerns about generalizability, regulatory issues, technical hurdles in implementation, and human skepticism. Further validation of AI tools for clinical use and demonstration of benefit in terms of patient-oriented outcomes also are needed. This article provides an overview of potential applications of AI tools in the imaging evaluation of lung nodules and discusses the challenges faced by practices interested in clinical implementation of such tools.
引用
- Liu, Yang, Tsai, et al. Artificial Intelligence (AI) for Lung Nodules, From the AJR Special Series on AI Applications. AJR Am J Roentgenol. 2022. PMID: 35544377. doi:10.2214/AJR.22.27487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。